{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:15:44Z","timestamp":1784754944644,"version":"3.55.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>To provide an overview of fibroblast growth factor receptor (FGFR) gene alterations and the pharmacology, clinical effectiveness, dosage and administration, cost, and place in therapy of erdafitinib in bladder cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Erdafitinib (Balversa, Janssen Pharmaceuticals) is a novel pan-FGFR inhibitor recently approved for the treatment of patients with advanced urothelial cancer with specific FGFR genetic alterations who have received at least one prior platinum-containing regimen. Erdafitinib binding to the FGFR2 and FGFR3 receptors inhibits FGF activity, resulting in cell death. Erdafitinib is available in tablet form, and the current recommended daily dosing is 8 mg, with dose escalation to 9 mg after 14 to 21 days of therapy if tolerated. A phase 2 clinical trial demonstrated that patients who received erdafitinib experienced on average 5.5 months of progression-free survival (95% confidence interval [CI], 4.2-6.0 months). In addition, 40% (95% CI, 31-50%) of patients responded to erdafitinib therapy. Patients receiving erdafitinib therapy should be monitored specifically for elevations in serum phosphate levels and changes in vision. Other adverse effects include anemia, thrombocytopenia, and electrolyte abnormalities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Erdafitinib is the first small-molecule FGFR inhibitor approved for use in advanced bladder cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxz329","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T09:17:43Z","timestamp":1582103863000},"page":"346-351","source":"Crossref","is-referenced-by-count":56,"title":["Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer"],"prefix":"10.1093","volume":"77","author":[{"given":"Kiera","family":"Roubal","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Wisconsin, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin W","family":"Myint","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M","family":"Kolesar","sequence":"first","affiliation":[{"name":"University of Kentucky College of Pharmacy, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"key":"2020021904093079000_CIT0001","author":"American Society of Clinical Oncology"},{"key":"2020021904093079000_CIT0002","author":"National Cancer Institute"},{"issue":"1","key":"2020021904093079000_CIT0003","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12885-019-5267-3","article-title":"Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis","volume":"19","author":"Al-Husseini","year":"2019","journal-title":"BMC Cancer."},{"issue":"1","key":"2020021904093079000_CIT0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin."},{"issue":"2","key":"2020021904093079000_CIT0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin."},{"key":"2020021904093079000_CIT0006","volume-title":"Key statistics for bladder cancer","author":"American Cancer Society","year":"2019"},{"key":"2020021904093079000_CIT0007","author":"National Comprehensive Cancer Network"},{"issue":"10","key":"2020021904093079000_CIT0008","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.mayocp.2017.07.010","article-title":"Management of muscle-invasive urothelial cancer and the emerging role of immunotherapy in advanced urothelial cancer","volume":"92","author":"Giridhar","year":"2017","journal-title":"Mayo Clin Proc."},{"key":"2020021904093079000_CIT0009","author":"National Comprehensive Cancer Network"},{"issue":"1","key":"2020021904093079000_CIT0010","first-page":"1","article-title":"Biomarkers for bladder cancer management: present and future","volume":"2","author":"Ye","year":"2014","journal-title":"Am J Clin Exp Urol."},{"key":"2020021904093079000_CIT0011","author":"National Cancer Institute"},{"issue":"4","key":"2020021904093079000_CIT0012","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.3390\/cancers10040100","article-title":"Bladder cancer: new insights into its molecular pathology","volume":"10","author":"Inamura","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2020021904093079000_CIT0013","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol."},{"issue":"4","key":"2020021904093079000_CIT0014","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1464-410X.2010.09912.x","article-title":"Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience","volume":"108","author":"Yafi","year":"2011","journal-title":"BJU Int."},{"issue":"1","key":"2020021904093079000_CIT0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer."},{"issue":"33","key":"2020021904093079000_CIT0016","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1200\/JCO.2008.21.4924","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy: phase II\u2013results of EORTC study 30986","volume":"27","author":"De Santis","year":"2009","journal-title":"J Clin Oncol."},{"issue":"10064","key":"2020021904093079000_CIT0017","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet."},{"issue":"11","key":"2020021904093079000_CIT0018","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"2020021904093079000_CIT0019","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"2020021904093079000_CIT0020","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (checkmate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10122","key":"2020021904093079000_CIT0021","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (imvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet."},{"issue":"1","key":"2020021904093079000_CIT0022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol."},{"key":"2020021904093079000_CIT0023","article-title":"Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma","volume":"35","author":"Powles","year":"2018","journal-title":"J Clin Oncol."},{"key":"2020021904093079000_CIT0024"},{"issue":"7463","key":"2020021904093079000_CIT0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature."},{"key":"2020021904093079000_CIT0026","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research N","year":"2014","journal-title":"Nature"},{"issue":"2","key":"2020021904093079000_CIT0027","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer."},{"issue":"2","key":"2020021904093079000_CIT0028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"2020021904093079000_CIT0029","doi-asserted-by":"crossref","first-page":"218142","DOI":"10.4061\/2010\/218142","article-title":"Fibroblast growth factors: biology, function, and application for tissue regeneration","volume":"2010","author":"Yun","year":"2010","journal-title":"J Tissue Eng."},{"issue":"2","key":"2020021904093079000_CIT0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGF receptors: cancer biology and therapeutics","volume":"34","author":"Katoh","year":"2014","journal-title":"Med Res Rev."},{"issue":"7","key":"2020021904093079000_CIT0031","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1349-7006.2008.00840.x","article-title":"Regulation of growth factor signaling by FRS2 family docking\/scaffold adaptor proteins","volume":"99","author":"Gotoh","year":"2008","journal-title":"Cancer Sci."},{"issue":"7","key":"2020021904093079000_CIT0032","first-page":"1","article-title":"Targeting cellular trafficking of fibroblast growth factor receptors as a strategy for selective cancer treatment","volume":"8","author":"Porebska","year":"2019","journal-title":"J. Clin. Med."},{"issue":"3","key":"2020021904093079000_CIT0033","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOU.0000000000000605","article-title":"Urinary biomarkers in bladder cancer: where do we stand?","volume":"29","author":"Bhat","year":"2019","journal-title":"Curr Opin Urol."},{"issue":"1","key":"2020021904093079000_CIT0034","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12894-018-0380-1","article-title":"Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Urol."},{"issue":"2","key":"2020021904093079000_CIT0035","first-page":"1","article-title":"Enrichment of FGFR3-TACC3 fusions in patients with bladder cancer who are young, Asian, or have never smoked","author":"Nassar","year":"2018","journal-title":"JCO Precis Oncol."},{"issue":"7","key":"2020021904093079000_CIT0036","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/1535-7163.MCT-12-1150","article-title":"Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer","volume":"12","author":"Gust","year":"2013","journal-title":"Mol Cancer Ther."},{"issue":"12","key":"2020021904093079000_CIT0037","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/JTO.0b013e31826aed28","article-title":"FGFR1 amplification in squamous cell carcinoma of the lung","volume":"7","author":"Heist","year":"2012","journal-title":"J Thorac Oncol."},{"issue":"5","key":"2020021904093079000_CIT0038","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/JTO.0b013e31819f2e38","article-title":"Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival","volume":"4","author":"Donnem","year":"2009","journal-title":"J Thorac Oncol."},{"issue":"5","key":"2020021904093079000_CIT0039","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res."},{"key":"2020021904093079000_CIT0040","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/oncsis.2013.4","article-title":"A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop","volume":"2","author":"Ware","year":"2013","journal-title":"Oncogenesis."},{"issue":"5","key":"2020021904093079000_CIT0041","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/156800909789057006","article-title":"The role of fibroblast growth factors in tumor growth","volume":"9","author":"Korc","year":"2009","journal-title":"Curr Cancer Drug Targets."},{"issue":"4","key":"2020021904093079000_CIT0042","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell."},{"key":"2020021904093079000_CIT0043","author":"Balversa [package insert]","year":"2019"},{"issue":"4","key":"2020021904093079000_CIT0044","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med."},{"key":"2020021904093079000_CIT0045","author":"ClinicalTrials.gov"},{"issue":"4","key":"2020021904093079000_CIT0046","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med."},{"issue":"9","key":"2020021904093079000_CIT0047","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","article-title":"Erdafitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs."},{"key":"2020021904093079000_CIT0048","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2369-16-9","article-title":"The \u201cphosphorus pyramid\u201d: a visual tool for dietary phosphate management in dialysis and CKD patients","volume":"16","author":"D\u2019Alessandro","year":"2015","journal-title":"BMC Nephrol."},{"key":"2020021904093079000_CIT0049","author":"Food and Drug Administration"},{"key":"2020021904093079000_CIT0050","volume-title":"Lexicomp Online [online database]","author":"Erdafitinib [monograph]"},{"issue":"2","key":"2020021904093079000_CIT0051","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol."},{"key":"2020021904093079000_CIT0052","author":"Janssen Prescription Assistance"},{"key":"2020021904093079000_CIT0053","author":"ClinicalTrials.gov"},{"key":"2020021904093079000_CIT0054","author":"ClinicalTrials.gov"},{"key":"2020021904093079000_CIT0055","author":"ClinicalTrials.gov"},{"key":"2020021904093079000_CIT0056","author":"ClinicalTrials.gov"},{"key":"2020021904093079000_CIT0057","author":"ClinicalTrials.gov"},{"key":"2020021904093079000_CIT0058","author":"ClinicalTrials.gov"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/5\/346\/32520054\/zxz329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/5\/346\/32520054\/zxz329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T09:18:01Z","timestamp":1582103881000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/5\/346\/5740303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":58,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,19]]},"published-print":{"date-parts":[[2020,2,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz329","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,1]]},"published":{"date-parts":[[2020,2,19]]}}}